European Companies Search Engine
EU funding (€3,940,389): TRAIN-HEART Hor26 Apr 2019 EU Research and Innovation programme "Horizon"
Overview
Text
TRAIN-HEART
TRAIN-HEART brings together leading academic teams and (biotech) companies to train the next-generation of innovation-minded researchers who can expand the scientific horizons and accelerate future development of RNA-based therapeutics for the treatment of ischemic heart failure. Under chronic cardiac stress, non-coding RNAs, in particular microRNAs and long non-coding RNAs, act as critical regulators of cardiac tissue remodelling. Innovative therapies targeting these RNA molecules hold great promise in treating the underlying causes of ischemic heart failure. With the exception of heart transplantation, there is no curative therapy available for this detrimental disease. Given the challenges related to delivery, specificity and tolerability of RNA therapeutics, developments in chemically modified oligonucleotides and drug delivery strategies are growing substantially. TRAIN-HEART’s proposition is to train a league of 15 promising fellows that harness novel insights in the pathogenesis of ischemic heart failure, study the therapeutic potential of existing RNA therapeutics and improve its efficacy by the design of novel drug delivery systems. TRAIN-HEART provides such training in a European network of top-level academic teams and (biotech) companies active in the fields of cardiovascular biology, functional genomics and drug development. All individual research projects demonstrate multidisciplinary content and supervision arrangements, momentous intersectoral exchanges and international synergies. These PhD programmes are complemented with the right combination of specialised research- and transferable skills trainings to encourage excellent science, innovation and long-term employability. The TRAIN-HEART fellows are envisioned to become entrepreneurial researchers who are keen to bring cutting-edge scientific concepts in RNA therapeutics to the clinic.
Funded Companies:
| Company name | Funding amount |
| ACCELERO BIOANALYTICS GmbH | ? |
| Humanitas Mirasole S.p.A. | €522,999 |
| King's College London | €606,345 |
| MEDIZINISCHE HOCHSCHULE HANNOVER | €252,788 |
| MILTENYI BIOTEC GmbH | €252,788 |
| €265,620 | |
| TECHNISCHE UNIVERSITAET MUENCHEN | €505,577 |
| €475,440 | |
| UNIVERSITAETSKLINIKUM HAMBURG-EPPENDORF | €252,788 |
| Universite Lyon 1 Claude Bernard | €274,802 |
| Universiteit Maastricht | €531,240 |
Source: https://cordis.europa.eu/project/id/813716
The filing refers to a past date, and does not necessarily reflect the current state. The current state is available on the following page: Accelero Bioanalytics GmbH, Berlin, Germany.
The visualizations for "ACCELERO BIOANALYTICS GmbH - EU funding (€3,940,389): TRAIN-HEART"
are provided by
North Data
and may be reused under the terms of the
Creative Commons CC-BY license.
